MassDevice.com +5 | The top 5 medtech stories for June 5, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. SentreHeart enters pivotal phase after hitting Lariat study milestone SentreHeart can launch the 2nd, pivotal phase in the Amaze study of its Lariat device, after hitting the mark in the 1st, 100-patient stage. Like the Watchman anti-stroke device made by Boston Scientific (NYSE:BSX), Lariat is designed to occlude the left atrial appendage, but unlike Watchman it’s intended to help treat atrial fibrillation alongside pulmonary vein isolation. The FDA approved an expansion of the study, which can now enroll another 500 patients after an independent data monitoring committee reviewed the data against preset safety and performance criteria, Redwood City, Calif.-based SentreHeart said. Read more 4. Medovex wins CE Mark for DenerveX spinal denervation system Medical technology portfolio company Medovex said today it won CE Mark approval in the European Union for its DenerveX spinal denervation treatment system designed to treat facet joint syndrome. The DenerveX system uses a slowly rotating burr to remove targeted facet joint synovial membrane and radiofrequency ablation tec...
Source: Mass Device - Category: Medical Devices Authors: Tags: News Well Plus 5 Source Type: news